AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval

As Humira competition heats up in Europe—and soon enough in the U.S.—AbbVie picked up an approval in Japan for IL-23 inhibitor Skyrizi. Analysts believe it can pull in $1.74 billion by 2023.